Novartis AG
Other OTCTotal Valuation
Novartis AG carries a market capitalization of 312.19B, placing it among publicly traded companies globally. Its enterprise value stands at 333.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 312.19B |
| Enterprise Value | 333.26B |
Share Statistics
Novartis AG currently has 1.90B shares outstanding.
| Shares Outstanding | 1.90B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Novartis AG trades at a trailing price-to-earnings ratio of 22.95. The price-to-sales ratio is 5.16, and the price-to-book ratio stands at 7.02.
| PE Ratio | 22.95 |
| PS Ratio | 5.16 |
| PB Ratio | 7.02 |
| P/TBV Ratio | -10.68 |
| P/FCF Ratio | 13.50 |
| P/OCF Ratio | 15.92 |
Enterprise Valuation
On an enterprise value basis, Novartis AG trades at an EV/EBITDA multiple of 14.72 and an EV/FCF ratio of 14.52. The EV/Sales ratio of 5.88 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.49 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.88 |
| EV / EBITDA | 14.72 |
| EV / EBIT | 19.49 |
| EV / FCF | 14.52 |
Financial Position
Novartis AG maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 116.85, indicating elevated leverage, while an interest coverage ratio of 16.29 demonstrates strong ability to service its debt obligations.
| Current Ratio | 0.86 |
| Quick Ratio | 0.55 |
| Debt / Equity | 116.85 |
| Debt / EBITDA | 2.16 |
| Interest Coverage | 16.29 |
Financial Efficiency
Novartis AG posts a return on equity of 30.55 and a return on invested capital of 16.45.
| Return on Equity (ROE) | 30.55 |
| Return on Assets (ROA) | 11.27 |
| Return on Invested Capital (ROIC) | 16.45 |
| Return on Capital Employed (ROCE) | 16.79 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.29 |
Taxes
Over the trailing twelve months, Novartis AG has paid 2.78B in income taxes, reflecting an effective tax rate of 17.88.
| Income Tax | 2.78B |
| Effective Tax Rate | 17.88 |
Stock Price Statistics
Novartis AG's stock has gained approximately 26.10365% over the past 52 weeks. The 50-day moving average sits at 155.44, while the 200-day moving average is 148.34.
| Beta (5Y) | N/A |
| 52-Week Price Change | 26.10365% |
| 50-Day Moving Average | 155.44 |
| 200-Day Moving Average | 148.34 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Novartis AG generated 56.69B in revenue and converted that into 12.76B in net income, yielding earnings per share of 6.64. EBITDA reached 22.65B, while operating income came in at 17.10B.
| Revenue | 56.69B |
| Gross Profit | 42.37B |
| Operating Income | 17.10B |
| Pretax Income | 15.52B |
| Net Income | 12.76B |
| EBITDA | 22.65B |
| EBIT | 17.10B |
| Earnings Per Share (EPS) | 6.64 |
Balance Sheet
Novartis AG holds 7.69B in cash and equivalents against 49.01B in total debt, resulting in a net debt position of 39.46B. Total book value stands at 41.54B, with working capital of -4.40B providing operational flexibility.
| Cash & Cash Equivalents | 7.69B |
| Total Debt | 49.01B |
| Net Debt | 39.46B |
| Equity (Book Value) | 41.54B |
| Book Value Per Share | 21.86 |
| Working Capital | -4.40B |
Cash Flow
Novartis AG produced 18.39B in operating cash flow over the past twelve months. After subtracting -3.41B in capital expenditures, free cash flow totaled 14.98B - equivalent to 7.85 per share.
| Operating Cash Flow | 18.39B |
| Capital Expenditures | -3.41B |
| Free Cash Flow | 14.98B |
| FCF Per Share | 7.85 |
Margins
Novartis AG operates with a gross margin of 74.74, reflecting its pricing power and cost economics. The operating margin of 30.17 and net profit margin of 22.50 provide insight into operational efficiency.
| Gross Margin | 74.74 |
| Operating Margin | 30.17 |
| Pretax Margin | 27.38 |
| Profit Margin | 22.50 |
| EBITDA Margin | 39.94 |
Dividends & Yields
The company's payout ratio of 71.19 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 4.75 |
| Dividend Yield | N/A |
| Payout Ratio | 71.19 |
| Shareholder Yield | -0.16 |
| FCF Yield | 7.41 |
Stock Splits
Novartis AG's most recent stock split took place on October 4, 2023 with a 200:211 split ratio.
| Last Split Date | 10/4/2023 |
| Split Ratio | 200:211 |
Scores
Novartis AG posts an Altman Z-Score of 5.26, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.26 |